Tailor-Made vaccine takes on tough melanoma

This early-phase study tested a personalized vaccine (NeoVax) made from each patient's unique tumor mutations, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 11 people with advanced melanoma that could not be removed by surgery. The main goal was to check safety and find the right dose. While the vaccine aims to train the immune system to attack cancer, patients may still need ongoing treatment, so this is considered disease control rather than a cure.